Regeneron Pharmaceuticals Profit Margin

Regeneron Pharmaceuticals's profit margin stands at 27.86% as of June 2026. That compares with 31.37% in the prior-year period — down 11.2% year over year. That is above the Healthcare sector average of 13.89%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Regeneron Pharmaceuticals reported 27.86% in profit margin versus 31.37% a year earlier — a 11.2% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Regeneron Pharmaceuticals sits higher the Healthcare benchmark (13.89%) with a profit margin of 27.86%. That is roughly 100.6% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of 27.86% for Regeneron Pharmaceuticals means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Regeneron Pharmaceuticals's profit margin evolved across reporting periods, while the comparison chart places REGN next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.